Lan-Lan Pan

Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer

Y. Shu, P. Seesaha, Fengjiao Zhao, 2021, OncoTargets and therapy.

A single-arm, open-label, phase II study investigating anti-HER2 ADC plus anti-PD-1 antibody in patients with unresectable locally advanced or metastatic BTC with HER2 overexpression.

Jinrong Qiu, H. Qiu, T. Zheng, 2023, Journal of Clinical Oncology.

Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial

Qiuping Liu, Yu-Dong Zhang, Fen-jing Guo, 2023, JHEP reports : innovation in hepatology.

OTT_A_269671 1873..1882

Fengjiao Zhao, Xiao-Feng Chen, Xiangcheng Li, 2021 .